Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.
It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation. Or, as noted by the Cleveland Clinic, when you have the wrong amount of genetic material. It’s even helped address a form of inherited blindness in patients, including children. According to Penn Medicine News, “nearly half reported measurable improvements in sight, including the two children according to the study.”
As noted by Precedence Research, all of these factors could help create a potential $29.93 billion market by 2032, based on today’s $6.94 billion valuation.
|
Company: CRISPR Therapeutics (SYM: CRSP) Look at CRISPR Therapeutics (SYM: CRSP), for example. Months ago, the company received U.S. FDA approval for its sickle-cell treatment and clearance for its treatment of transfusion-dependent beta-thalassemia (TDT). While CRISPR is still one of the top gene editing stocks to buy, there are others with just as much promise. |
Oxford Club
Seven Must-Own Stocks for AI Investors
Discover AI’s “Next Magnificent Seven” Here.
|
Company: Intellia Therapeutics (SYM: NTLA) Look at Intellia Therapeutics (SYM: NTLA), for example. Just weeks ago, the company reported positive long-term data from a Phase 1 study of NTLA-2002 for treating hereditary angioedema (HAE), which impacts one in 50,000 people. According to the company, a single dose led to a 98% mean reduction in the monthly attack rate, with an average follow-up of over 20 months across all patients. It added that eight out of ten patients were completely attack-free following a 16-week primary observation period through the last follow-up, including patients with the most severe disease. The company expects to report Phase 2 results this year and start Phase 3 trials this year. |
InvestorPlace
Forget AI THIS is Way Bigger
While the world has been obsessed with AI and ChatGPT… Jeff Bezos has quietly gone all in on a technology that’s going to prove to be FAR bigger.
If you’ve never heard of “QaaS” technology you need to click here now.
|
Company: Beam Therapeutics (SYM: BEAM) There’s Beam Therapeutics (SYM: BEAM), which develops BEAM-101 for sickle cell and beta-thalassemia; BEAM-302 for the treatment of severe alpha-1 antitrypsin deficiency; and BEAM-201 for refractory T-cell acute lymphoblastic leukemia / T-cell lymphoblastic lymphoma. And while earnings haven’t been anything to write home about just yet, that should change with successful trial results. In its most recent quarter, the company posted a Q2 earnings per share loss of $1.11, which beat by a penny. Revenue of $11.77 million also missed by $1.28 million. |
